Saturday, September 25

EANO Meeting - Saturday, September 25, 2021

All times below refer to Central European Summer Time (CEST).

09:00-10:00 hrs

Chairs: Alessia Pellerino, George Petrescu

JS01.1 Vasculogenic mimicry: potential therapeutic target of glioma
Zhongping Chen, China

JS01.2 Surgery or chemotherapy in lower-grade glioma?
Amélie Darlix, France

Chair: Emilie Le Rhun

OS01.1 Women's perspective
Estela Pineda, Spain
Susan Short, United Kingdom
Karin Piil, Denmark
Julia Furtner-Srajer, Austria

OS01.2 Disparity of care
Bozena Kaminska, Poland
Tomas Kazda, Czech Republic
Pieter Wesseling, Netherlands
Simone Niclou, Luxembourg
Maciej Mrugala, United States

Chairs: Elizabeth Cohen-Moyal, Anthony Chalmers

WS01.1 Optimzing radiotherapy using Nanoparticles
Karl Butterworth, United Kingdom

WS01.2 Intrinsic radioresistance and FGFR pathway
Elizabeth Cohen-Moyal, France

WS01.3 Aberrant DNA repair as a therapeutic target in glioblastoma
Petra Hamerlik, Denmark


10:00-10:30 hrs | BREAK


10:30-12:00 hrs

Chairs: Mihaela Lorger, Michael Platten

KS01.1 Acquired immune system (T cells)
Burkhard Becher, Switzerland

KS01.2 Exploring and Therapeutically Exploiting the Brain Tumour Microenvironment
Johanna Joyce, Switzerland

Chairs: Oliver Hanemann, Matthias Preusser

OS02.1 Impact of tumor plasticity on experimental therapies for brain metastases
Manuel Valiente, Spain

OS02.2 Tumor plasticity from a neurosurgical perspective

Colin Watts, United Kingdom

OS02.3 Your viewpoint on the impact of tumor heterogeneity on experimental therapies
Wolfgang Wick, Germany

Chairs: Elizabeth Cohen-Moyal, Anthony Chalmers

OS03.1 Carbon ion therapy for brain tumours in theory and in practice
Stephanie Combs, Germany

OS03.2 Proton beam therapy for adult brain tumours: pros and cons
Gillian Whitfield, United Kingdom


12:00-12:30 hrs | BREAK


12:30-13:45 hrs

Corporate Symposia


13:45-14:00 hrs | BREAK


14:00-14:45 hrs

E-Poster Viewing with authors


14:45-15:00 hrs | BREAK


15:00-16:00 hrs

Chairs: Roberta Rudà, Martin van den Bent

ME01.1 Medulloblastoma: a multicenter trial in adult patients
Peter Hau, Germany

ME01.2 EURACAN and CNS tumors: background of the effort
Ahmed Idbaih, France

ME01.3 NTRK fusions and glioma
Evangelia Razis, Greece

Chairs: Asgeir Jakola, tba

ME02.1 Continous dynamic mapping for removal of brain tumors in eloquent brain regions
Kathleen Seidel, Switzerland

ME02.2 Laser ablation - Indications in Neuro-oncology
Mark ter Laan, Netherlands

ME02.3 Integrated Classification of Meningiomas
Gelareh Zadeh, Canada

Chairs: Marjolein Guerts, Simona Gaito

WS02.1 You cannot not communicate
Eva Masel, Austria

WS02.2 Palliative care and end-of-life management in brain tumors
Andrea Pace, Italy


16:00-16:30 | BREAK


16:30-18:00 hrs

Chairs: Simone Niclou, Pim French

PL02.1 Cancer dependency maps
Mathew Garnett, United Kingdom

PL02.2 Exceptional Responders: Inferences from N of 1 Experiments
David Wheeler, United States


18:00-18:30 hrs | BREAK


18:30-20:00 hrs

Chairs: Patrick Roth, tba

JS02.1 Treatment Monitoring in Brain tumors: New Insights by Amino Acid PET, „ImmunoPET“ and PET Radiomics?
Norbert Galldiks, Germany

JS02.2 TSPO – a new tracer for imaging glioma and microglia
Jörg Tonn, Germany

JS02.3 Theranostics of the brain
Tatjana Traub-Weidinger, Austria

Chairs: Susan Chang, Wolfgang Wick

JS03.1 Evidence based: 6 cycles of adjuvant temozomide suffices in glioblastoma
Carmen Balanà Quintero, Spain

JS03.2 IDH inhibitors: early signs of activity?
Ingo Mellinghof, United States

JS03.3 Detection and discrimination of intracranial tumors by blood
Farshad Nassiri, Canada

JS03.4 Synaptic communication in brain tumours
Varun Venkataramani, Germany

Chairs: Martin van den Bent, tba

JS04.1 When and why to perform repeated surgery for progressive LGG
Lorenzo Bello, Italy

JS04.2 Systemic therapies for intracranial metastasis, what are the options and when to refer for local therapy?
Anna Berghoff, Austria

JS04.3 Neurosurgical and radiosurgical decision making in patients with brain metastases in the era of personalized medicine
Philippe Métellus, France

JS04.4 Oncological treatment in progressive LGG following surgery - or should  all be treated upfront?
Martin van den Bent, Netherlands


Note that the programme is subject to change and will be continuously updated.